Dr. Jonathan K.C. Knowles

Dr. Jonathan K.C. Knowles Dr. Knowles was Head of Group Research and Member of the Executive Committee at Roche up to the end of 2009. He was a member of the Genentech Board for the last 12 years and a member of the Chugai Board for seven years. Dr. Knowles was also the chairman of the Corporate Governance Committee of Genentech. Dr. Knowles focused the company on key disease biology areas of high medical need and in-depth understanding of molecular pathology of disease. Under his leadership, the company developed and implemented a strategy of highly effective therapies based on personalized healthcare. He was for 5 years the Chairman of the Research Directors’ Group of EFPIA (European Federation of Pharmaceutical Industry Associations) and was the first chairman of the Board of the Innovative Medicines Initiative, a unique public-private partnership between 28 Pharmaceutical companies and the European Commission with a budget of more than 2 Billion Euros over five years. Prior to this he served as Director of the Glaxo Institute in Geneva for 10 years and as head of European Research for Glaxo Wellcome. Dr. Knowles attended Magdalen College School in Oxford and received a First Class Honours Degree in Molecular Genetics from the University of East Anglia in Norwich, England. He received his Ph.D. in Genetics of Mitochondria with Professor G. H. Beale F.R.S. from the University of Edinburgh in Scotland. Jonathan Knowles holds a Distinguished Professorship in Personalized medicine at FIMM (Institute for Molecular Medicine Finland) at the University of Helsinki, was recently appointed Professor of Translational Medicine at EPFL in Switzerland, and has been appointed to a Visiting chair at the University of Oxford. In addition, he is a Member of the European Molecular Biology Organization and a Visiting Fellow of Pembroke College Cambridge. He is also a Member of EMBO (the European Molecular Biology Organisation). In 2011, Jonathan Knowles was appointed as a Trustee of Cancer Research UK, one of the world’s leading Cancer Research Organisarions. He serves as a non executive member of a number of Biotech company boards and on international scientific advisory boards of several Public Organisations.